var data={"title":"Approach to the patient with thrombocytosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Approach to the patient with thrombocytosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/contributors\" class=\"contributor contributor_credentials\">Ayalew Tefferi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/contributors\" class=\"contributor contributor_credentials\">Lawrence LK Leung, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/contributors\" class=\"contributor contributor_credentials\">Alan G Rosmarin, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Mar 29, 2018.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thrombocytosis refers to an increased platelet count which, in this review, is <span class=\"nowrap\">&gt;450,000/microL</span> (&gt;450 x 10<sup>9</sup><span class=\"nowrap\">/L)</span>.</p><p>This topic discusses our approach to the adult or child with unexplained thrombocytosis.</p><p>Clinical manifestations and diagnosis of specific causes of thrombocytosis are discussed separately. (See <a href=\"topic.htm?path=diagnosis-and-clinical-manifestations-of-essential-thrombocythemia\" class=\"medical medical_review\">&quot;Diagnosis and clinical manifestations of essential thrombocythemia&quot;</a> and <a href=\"topic.htm?path=overview-of-the-myeloproliferative-neoplasms\" class=\"medical medical_review\">&quot;Overview of the myeloproliferative neoplasms&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2635508307\"><span class=\"h1\">DEFINITIONS AND NORMAL VALUES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following terms, definitions, and values are used in this topic:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Platelets</strong> &ndash; Platelets are cellular fragments that are derived from megakaryocytes in the bone marrow, as described separately. (See <a href=\"topic.htm?path=platelet-biology\" class=\"medical medical_review\">&quot;Platelet biology&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Normal platelet count</strong> &ndash; The normal platelet count in adults and children is 150,000 to <span class=\"nowrap\">450,000/microL</span> (150 to 450 x 10<sup>9</sup><span class=\"nowrap\">/L),</span> but the range may vary in clinical laboratories.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Thrombocytosis</strong> &ndash; Thrombocytosis is a platelet count <span class=\"nowrap\">&gt;450,000/microL</span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Extreme thrombocytosis</strong> &ndash; Extreme thrombocytosis is a platelet count <span class=\"nowrap\">&ge;1,000,000/microL</span>.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Autonomous thrombocytosis</strong> &ndash; Autonomous (primary) thrombocytosis is caused by a cell-intrinsic mechanism (ie, a process that arises from within the megakaryocyte or its precursor cells). (See <a href=\"#H404271305\" class=\"local\">'Autonomous thrombocytosis'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Reactive thrombocytosis</strong> &ndash; Reactive (secondary) thrombocytosis refers to thrombocytosis caused by a process that is extrinsic to megakaryocytes. (See <a href=\"#H2536454853\" class=\"local\">'Reactive thrombocytosis'</a> below.)</p><p/><p class=\"headingAnchor\" id=\"H352081854\"><span class=\"h1\">CAUSES OF THROMBOCYTOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thrombocytosis can be caused by either reactive or autonomous processes, as described below.</p><p>Platelets are anucleate cellular fragments derived from megakaryocytes in the bone marrow. Regulation of thrombopoiesis (platelet production) is discussed separately. (See <a href=\"topic.htm?path=megakaryocyte-biology-and-the-production-of-platelets#H12\" class=\"medical medical_review\">&quot;Megakaryocyte biology and the production of platelets&quot;, section on 'Regulation of platelet production'</a> and <a href=\"topic.htm?path=platelet-biology#H2\" class=\"medical medical_review\">&quot;Platelet biology&quot;, section on 'Overview of platelet function'</a>.)</p><p>Causes of thrombocytosis vary based on the population studied. As examples, causes of thrombocytosis differ in ambulatory versus hospitalized patients and in infants versus adults.</p><p class=\"headingAnchor\" id=\"H2536454853\"><span class=\"h2\">Reactive thrombocytosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reactive<strong> </strong>processes, also described as secondary thrombocytosis, are caused by processes that are extrinsic to the megakaryocyte. Reactive processes account for most cases of thrombocytosis in all age groups and clinical settings.</p><p>Common causes of reactive thrombocytosis (<a href=\"image.htm?imageKey=HEME%2F74148\" class=\"graphic graphic_table graphicRef74148 \">table 1</a>) include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><span class=\"nowrap\">Anemia/Blood</span> loss</strong> &ndash; Iron deficiency, blood loss, hemolysis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Infection</strong> &ndash; Viral, bacterial, mycobacterial, and fungal causes</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Non-infectious inflammation</strong> &ndash; Malignancy, rheumatologic conditions, trauma, reactions to medications</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Post-splenectomy</strong> &ndash; Post-splenectomy or functional asplenia (eg, sickle cell disease)</p><p/><p>Mechanisms of reactive thrombocytosis vary with the underlying cause, and may include increased megakaryocyte <span class=\"nowrap\">proliferation/maturation,</span> accelerated platelet release, <span class=\"nowrap\">and/or</span> reduced platelet <span class=\"nowrap\">sequestration/turnover</span>. As examples, asplenia is associated with decreased platelet <span class=\"nowrap\">sequestration/turnover</span>. Blood <span class=\"nowrap\">loss/iron</span> deficiency is associated with increased proliferation of progenitor cells that are common to both platelets and red blood cells. In infections and inflammatory processes, increased production of cytokines stimulate megakaryocyte proliferation, maturation, <span class=\"nowrap\">and/or</span> accelerated platelet release. (See <a href=\"topic.htm?path=megakaryocyte-biology-and-the-production-of-platelets#H12\" class=\"medical medical_review\">&quot;Megakaryocyte biology and the production of platelets&quot;, section on 'Regulation of platelet production'</a>.)</p><p class=\"headingAnchor\" id=\"H404271305\"><span class=\"h2\">Autonomous thrombocytosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Autonomous (primary)<strong> </strong>thrombocytosis is caused by cell-intrinsic mechanisms (ie, processes that lay within the megakaryocyte or its precursor cells).</p><p>Most autonomous thrombocytosis in adults is <strong>clonal</strong> (ie, malignant), and is caused by <strong>acquired</strong> (somatic) mutations of genes which regulate thrombopoiesis (eg, <em>JAK2, CALR, </em>or <em>MPL</em>) and that are associated with myeloproliferative neoplasms (MPN) and other hematologic malignancies. (See <a href=\"#H1947117540\" class=\"local\">'Hematologic malignancies'</a> below.)</p><p>Thrombocytosis in infants and children may be caused by acquired mutations or, rarely, by <strong>inherited</strong> (ie, germline) genetic abnormalities associated with familial thrombocytosis syndromes, as described below. (See <a href=\"#H2724242692\" class=\"local\">'Familial thrombocytosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H1947117540\"><span class=\"h3\">Hematologic malignancies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Hematologic malignancies that are associated with thrombocytosis include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Essential thrombocythemia</strong> &ndash; Essential thrombocythemia (ET) is an MPN that is manifest as thrombocytosis, often in association with vasogenic symptoms (eg, flushing, erythromelalgia) <span class=\"nowrap\">and/or</span> thrombo-hemorrhagic complications. ET is generally caused by an acquired mutation of <em>JAK2, CALR, </em>or <em>MPL</em>. Other clinical manifestations and diagnosis of ET are discussed separately. (See <a href=\"topic.htm?path=diagnosis-and-clinical-manifestations-of-essential-thrombocythemia\" class=\"medical medical_review\">&quot;Diagnosis and clinical manifestations of essential thrombocythemia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Polycythemia vera</strong> &ndash; Polycythemia vera (PV) is an MPN that is manifest as polycythemia (elevated hemoglobin <span class=\"nowrap\">and/or</span> hematocrit) and is often accompanied by thrombocytosis; thrombo-hemorrhagic complications; splenomegaly; pruritus, flushing, erythromelalgia; <span class=\"nowrap\">and/or</span> constitutional symptoms (eg, fever sweats, weight loss). PV is nearly invariably associated with an acquired mutation of <em>JAK2</em>. Other clinical manifestations and diagnosis of PV are discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of polycythemia vera&quot;</a> and <a href=\"topic.htm?path=diagnostic-approach-to-the-patient-with-polycythemia\" class=\"medical medical_review\">&quot;Diagnostic approach to the patient with polycythemia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Primary myelofibrosis</strong> &ndash; Primary myelofibrosis (PMF) is an MPN in which bone marrow fibrosis and a leukoerythroblastic blood smear may be accompanied by thrombocytosis, splenomegaly, thrombo-hemorrhagic complications, <span class=\"nowrap\">and/or</span> constitutional symptoms. Approximately 90 percent of cases have a mutation in <em>JAK2, CALR</em>, or <em>MPL.</em> Clinical manifestations and diagnosis of PMF are discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-primary-myelofibrosis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of primary myelofibrosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Chronic myeloid leukemia</strong> &ndash; Chronic myeloid leukemia (CML) is an MPN in which a characteristic chromosomal abnormality, t(9;22), the Philadelphia chromosome, generates the <em>BCR-ABL1</em> oncogene. CML is clinically manifest as an increase of immature myeloid cells in peripheral blood and bone marrow, often accompanied by thrombocytosis, polycythemia, <span class=\"nowrap\">and/or</span> splenomegaly, as discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-chronic-myeloid-leukemia\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of chronic myeloid leukemia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Myelodysplastic syndromes</strong> &ndash; Myelodysplastic syndromes (MDS) are occasionally associated with thrombocytosis. The 5q- syndrome and <span class=\"nowrap\">MDS/MPN</span> with ring sideroblasts and thrombocytosis are the MDS categories that are most commonly associated with thrombocytosis. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-the-myelodysplastic-syndromes#H1583841\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of the myelodysplastic syndromes&quot;, section on 'MDS/MPN with ring sideroblasts and thrombocytosis'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Acute myeloid leukemia</strong> &ndash; Acute myeloid leukemia (AML) is occasionally associated with thrombocytosis. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-myeloid-leukemia#H12\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia&quot;, section on 'Pathologic features'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2724242692\"><span class=\"h3\">Familial thrombocytosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Familial thrombocytosis (also called familial essential thrombocythemia) refers to rare inherited syndromes that are manifest by thrombocytosis alone (ie, not associated with leukocytosis or polycythemia). Familial thrombocytosis exhibits Mendelian inheritance, high penetrance, and polyclonal hematopoiesis [<a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/1\" class=\"abstract_t\">1</a>]. Activating mutations of the thrombopoietin gene (<em>TPO</em>) or <em>MPL</em> have been described, as discussed in more detail separately. (See <a href=\"topic.htm?path=diagnosis-and-clinical-manifestations-of-essential-thrombocythemia#H26\" class=\"medical medical_review\">&quot;Diagnosis and clinical manifestations of essential thrombocythemia&quot;, section on 'Familial essential thrombocythemia'</a>.)</p><p>Rarely, thrombocytosis is associated with familial PV or PMF; these syndromes exhibit low penetrance, clonal hematopoiesis, and may be associated with <em>JAK2</em> V617F mutation [<a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/1\" class=\"abstract_t\">1</a>].</p><p class=\"headingAnchor\" id=\"H1020354520\"><span class=\"h1\">INITIAL EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Thrombocytosis may be encountered in the course of evaluating other clinical findings or as an incidental abnormality on a complete blood count (CBC) and differential.</p><p>Evaluation should include determination of the cause of thrombocytosis and prompt assessment for medical emergencies. Management of complications and emergency conditions should not be delayed by evaluation of the cause of thrombocytosis.</p><p class=\"headingAnchor\" id=\"H3427437341\"><span class=\"h2\">Urgency of evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The urgency of evaluation is guided by the patient's clinical condition, the presence of worrisome findings, and the degree of thrombocytosis.</p><p>As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical emergencies (eg, hemodynamic instability, respiratory compromise) or leukemic blasts on the blood smear generally require hospitalization for urgent evaluation and management.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Management of associated conditions (eg, thrombosis, bleeding) may require hospitalization and should not be delayed by evaluation of the cause of thrombocytosis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The asymptomatic patient without worrisome findings on the blood smear may be evaluated as an outpatient, and the urgency is influenced by the level of thrombocytosis:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Platelet count <span class=\"nowrap\">&ge;1,000,000/microL</span> should be promptly confirmed with a repeat CBC within one to two days</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Lower levels of thrombocytosis should be confirmed with a repeat CBC within one to two weeks</p><p/><p class=\"headingAnchor\" id=\"H1531610461\"><span class=\"h2\">Our approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>All patients with thrombocytosis should have a repeat CBC and differential count, review of the blood smear, history and physical examination, and certain other laboratory tests, as described in the sections that follow.</p><p>Specific causes of thrombocytosis that are identified by the initial evaluation and their management are discussed below. (See <a href=\"#H503942772\" class=\"local\">'Diagnosis established by initial evaluation'</a> below.)</p><p>Initial evaluation should identify patients who are more likely to have an autonomous (ie, malignant or inherited) disorder, because they may require additional testing, as described below. (See <a href=\"#H1561132762\" class=\"local\">'Other scenarios'</a> below.)</p><p>Patients with the following findings are more likely to have an autonomous cause for thrombocytosis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unexplained vasomotor symptoms (eg, erythromelalgia, flushing, pruritus), constitutional symptoms (eg, unexplained fever, sweats, or weight loss), <span class=\"nowrap\">and/or</span> splenomegaly. Such patients should be evaluated for a potential myeloproliferative neoplasm (MPN), as described below. (See <a href=\"#H2736885280\" class=\"local\">'Suspected myeloproliferative neoplasm'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thrombosis at unusual sites (eg, hepatic vein, inferior vena cava [Budd-Chiari syndrome], portal vein, splenic vein) or multiple sites, thrombosis in younger patients (eg, &lt;45 years), or unprovoked or recurrent thrombosis without other explanation should prompt evaluation for a potential MPN. (See <a href=\"#H2736885280\" class=\"local\">'Suspected myeloproliferative neoplasm'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Blood smear that reveals leukemic blasts, leukoerythroblastic features, or other evidence of leukemia or related hematologic malignancy should be referred promptly to a hematologist for further evaluation and management. (See <a href=\"#H2919826695\" class=\"local\">'Abnormal blood smear'</a> below.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Family history of unexplained thrombocytosis should be referred to a hematologist with expertise in inherited hematopoietic disorders. (See <a href=\"#H2528205724\" class=\"local\">'Familial thrombocytosis'</a> below.)</p><p/><p>Management of complications associated with thrombocytosis (eg, bleeding, thrombosis, vasomotor symptoms) is discussed below. (See <a href=\"#H28\" class=\"local\">'Management'</a> below.)</p><p class=\"headingAnchor\" id=\"H2977161337\"><span class=\"h2\">Complete blood count (CBC)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>CBC with differential count should be repeated to confirm the level of thrombocytosis. The urgency of repeat testing is informed by the criteria described above. (See <a href=\"#H3427437341\" class=\"local\">'Urgency of evaluation'</a> above.)</p><p>Spurious thrombocytosis should be excluded by review of the blood smear, as described below. (See <a href=\"#H3885038087\" class=\"local\">'Blood smear'</a> below.)</p><p>When available, prior CBCs (both normal and abnormal) can provide valuable information about the duration and trajectory of thrombocytosis.</p><p>Clues to the cause of thrombocytosis may come from other findings on the CBC. As examples, microcytic red blood cells (RBC) may indicate iron deficiency anemia, while neutrophilia may be caused by an infection or an inflammatory condition.</p><p>The normal mean platelet volume (MPV) is 9 to 10 femtoL (fL) in most clinical laboratories. The MPV cannot identify the specific cause of thrombocytosis, but MPV &ge;11 fL may indicate the presence of abnormal platelets (eg, MPN or familial platelet disorder) or younger platelets (eg, due to excessive platelet destruction).</p><p>A platelet count <span class=\"nowrap\">&ge;1,000,000/microL</span> (extreme thrombocytosis) may be caused by either a reactive cause or an autonomous (malignant) process. A single institution study reported that three-quarters of 280 consecutive patients with a platelet count <span class=\"nowrap\">&gt;1,000,000/microL</span> had an underlying reactive process [<a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Less extreme thrombocytosis is most commonly due to iron deficiency, infectious or non-infectious inflammatory conditions, or recovery from thrombocytopenia (eg, after chemotherapy or vitamin repletion).</p><p class=\"headingAnchor\" id=\"H3885038087\"><span class=\"h2\">Blood smear</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The blood smear should be reviewed to assess platelet morphology, detect other hematologic abnormalities, and exclude spurious thrombocytosis (pseudothrombocytosis).</p><p>Findings from the blood smear that may be useful in the evaluation of thrombocytosis include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Platelets</strong> &ndash; Platelet abnormalities include (see <a href=\"topic.htm?path=evaluation-of-the-peripheral-blood-smear#H20\" class=\"medical medical_review\">&quot;Evaluation of the peripheral blood smear&quot;, section on 'Platelets'</a>):</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Large platelets (up to the size of normal RBCs) may reflect a malignant process (eg, MPN), younger platelets associated with a reactive process (eg, excessive platelet destruction), or a familial platelet disorder.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Giant platelets (ie, larger than normal RBCs) may be seen with malignant or familial disorders, and less commonly with reactive thrombocytosis.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Giant platelets, platelet conglomerates, bizarre forms, megakaryocytic fragments, and platelet hypogranularity may be seen in some cases of malignant (<a href=\"image.htm?imageKey=HEME%2F61742\" class=\"graphic graphic_picture graphicRef61742 \">picture 1</a>) or familial thrombocytosis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Other lineages</strong> &ndash; Examples of abnormal findings in other lineages include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Howell-Jolly bodies (<a href=\"image.htm?imageKey=HEME%2F60588\" class=\"graphic graphic_picture graphicRef60588 \">picture 2</a>) <span class=\"nowrap\">and/or</span> nucleated RBCs (<a href=\"image.htm?imageKey=HEME%2F50601\" class=\"graphic graphic_picture graphicRef50601 \">picture 3</a>) may be seen with asplenia (surgical or functional). (See <a href=\"topic.htm?path=evaluation-of-the-peripheral-blood-smear#H24\" class=\"medical medical_review\">&quot;Evaluation of the peripheral blood smear&quot;, section on 'Red cell inclusions and other changes'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Myelophthisic disorders, including leukoerythroblastosis (<a href=\"image.htm?imageKey=HEME%2F68110\" class=\"graphic graphic_picture graphicRef68110 \">picture 4</a>), teardrop RBCs, nucleated RBCs, or immature granulocytes suggest an infiltrative process in the bone marrow. (See <a href=\"topic.htm?path=evaluation-of-the-peripheral-blood-smear#H36\" class=\"medical medical_review\">&quot;Evaluation of the peripheral blood smear&quot;, section on 'Leukoerythroblastic smear'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Immature leukocytes (eg, myeloblasts, promyelocytes, myelocytes) may be seen with chronic myeloid leukemia (<a href=\"image.htm?imageKey=HEME%2F56954\" class=\"graphic graphic_picture graphicRef56954 \">picture 5</a>) or other MPNs. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-chronic-myeloid-leukemia#H5\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of chronic myeloid leukemia&quot;, section on 'Peripheral blood'</a> and <a href=\"topic.htm?path=overview-of-the-myeloproliferative-neoplasms\" class=\"medical medical_review\">&quot;Overview of the myeloproliferative neoplasms&quot;</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Dysplastic neutrophils or the Pelger-Huet anomaly (<a href=\"image.htm?imageKey=HEME%2F71990\" class=\"graphic graphic_picture graphicRef71990 \">picture 6</a>) may indicate a myelodysplastic syndrome. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-the-myelodysplastic-syndromes#H33613152\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of the myelodysplastic syndromes&quot;, section on 'Peripheral blood smear'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Spurious thrombocytosis</strong> &ndash; Spurious thrombocytosis (pseudothrombocytosis) refers to an elevated platelet count on the CBC that does not correspond to the estimate from the blood smear. Multiplying by <span class=\"nowrap\">10,000/microL</span> the average number of platelets per high power field (hpf; under 100X oil immersion) provides a rough estimate of the platelet count. As an example, if the average number platelets is 25 per hpf, the platelet count would be estimated as <span class=\"nowrap\">250,000/microL</span>.</p><p/><p class=\"bulletIndent1\">Conditions that may cause spurious thrombocytosis include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Mixed cryoglobulinemia</strong> &ndash; Patients with mixed cryoglobulinemia may have a temperature-dependent increase in platelet count when blood samples are tested at &le;30&deg;C because of precipitated cryoglobulin particles that are counted as platelets in automated cell counters [<a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/3\" class=\"abstract_t\">3</a>]. This effect disappears if the blood sample is maintained at body temperature until testing.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Cytoplasmic fragments</strong> &ndash; Rarely, circulating cytoplasmic fragments (eg, leukemia or lymphoma cells) or fragmented RBCs (eg, from severe hemolysis or burns) may be erroneously interpreted as platelets by automated cell counters [<a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/4-6\" class=\"abstract_t\">4-6</a>].</p><p/><p class=\"headingAnchor\" id=\"H2380812066\"><span class=\"h2\">History and examination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>History should evaluate the following in relation to causes or complications of thrombocytosis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Recent trauma or surgery</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prior surgical removal of the spleen</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Findings suggesting infection or inflammation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>History of bleeding (eg, menorrhagia, gastrointestinal) or iron deficiency</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>History of arterial <span class=\"nowrap\">and/or</span> venous thrombosis</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Medications</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Smoking and alcohol consumption</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Prior diagnosis of a chronic hematologic disorder</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Unexplained fever, sweats, weight loss, fatigue, or other systemic complaints suggesting malignancy</p><p/><p>Physical examination should seek evidence of cutaneous or mucosal <span class=\"nowrap\">bleeding/bruising,</span> lymphadenopathy, hepatosplenomegaly, and findings suggestive of arterial or venous thrombosis.</p><p class=\"headingAnchor\" id=\"H1864706616\"><span class=\"h2\">Other laboratory studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Other laboratory studies useful for the initial evaluation of thrombocytosis follow:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Iron studies</strong> &ndash; Serum ferritin should be included in the initial evaluation of thrombocytosis; some experts also include serum iron and iron binding capacity. Evaluation of iron studies is discussed separately. (See <a href=\"topic.htm?path=causes-and-diagnosis-of-iron-deficiency-and-iron-deficiency-anemia-in-adults#H23\" class=\"medical medical_review\">&quot;Causes and diagnosis of iron deficiency and iron deficiency anemia in adults&quot;, section on 'Diagnostic evaluation'</a>.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>A low serum ferritin level (eg, &lt;15 <span class=\"nowrap\">ng/microL)</span> is diagnostic of iron deficiency, with a specificity approaching 100 percent. Patients with iron deficiency and anemia typically have microcytic, hypochromic RBCs on the CBC and blood smear (<a href=\"image.htm?imageKey=HEME%2F64267\" class=\"graphic graphic_picture graphicRef64267 \">picture 7</a>).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Elevated ferritin may reflect an inflammatory condition (ferritin is an acute phase reactant) or iron overload.</p><p/><p>In select patients, other laboratory tests may be useful. Examples include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Inflammatory markers</strong> &ndash; Erythrocyte sedimentation rate (ESR) <span class=\"nowrap\">and/or</span> C-reactive protein (CRP) may be useful in a patient suspected of having an inflammatory process, but who lacks other characteristic findings (eg, neutrophilia, toxic granulations, or Dohle bodies (<a href=\"image.htm?imageKey=HEME%2F70248\" class=\"graphic graphic_picture graphicRef70248 \">picture 8</a>)).</p><p/><p class=\"bulletIndent1\">ESR <span class=\"nowrap\">and/or</span> CRP should be normal with uncomplicated autonomous thrombocytosis, but elevated in most cases of reactive thrombocytosis. However, normal values for ESR and CRP do not exclude a reactive process.</p><p/><p>We suggest <strong>not</strong> routinely testing the following in the initial evaluation of thrombocytosis:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Serum chemistries &ndash; </strong>We do not routinely obtain liver or kidney function tests because they rarely identify a cause of thrombocytosis.</p><p/><p class=\"bulletIndent1\">Pseudohyperkalemia (artifactual elevation of potassium in <strong>serum </strong>but not in <strong>plasma</strong>) may be seen with thrombocytosis. Pseudohyperkalemia can occur when large numbers of platelets aggregate in vitro; this artifact does not occur in the patient and does not cause clinical problems. Pseudohyperkalemia can be confirmed by simultaneously testing the serum and plasma levels of potassium.<strong> </strong>(See <a href=\"topic.htm?path=causes-and-evaluation-of-hyperkalemia-in-adults#H4\" class=\"medical medical_review\">&quot;Causes and evaluation of hyperkalemia in adults&quot;, section on 'Pseudohyperkalemia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Platelet function testing </strong>&ndash; Platelet function studies do not identify the cause of thrombocytosis, but may be abnormal in some disorders, such as MPNs. Platelet function testing is discussed separately. (See <a href=\"topic.htm?path=platelet-function-testing\" class=\"medical medical_review\">&quot;Platelet function testing&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Flow cytometry</strong> &ndash; Flow cytometry is generally not useful for defining the cause of thrombocytosis, unless other findings suggest the presence of acute leukemia or related disorders. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-myeloid-leukemia\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Cytokines</strong> &ndash; There is no evidence that serum levels of thrombopoietin (TPO) or other cytokines can identify the cause of thrombocytosis or distinguish reactive from autonomous processes [<a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/7-10\" class=\"abstract_t\">7-10</a>].</p><p/><p class=\"headingAnchor\" id=\"H73021206\"><span class=\"h1\">FURTHER EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Our approach to further evaluation is guided by whether findings from the initial evaluation defined the cause of thrombocytosis.</p><p>The initial evaluation may identify more than one possible cause of thrombocytosis. As an example, a patient may have thrombocytosis in the setting of iron deficiency due to an underlying gastrointestinal malignancy. Remediable causes (eg, iron deficiency) should be treated while the underlying condition (eg, cancer) is addressed.</p><p>Management of medical complications (eg, hemorrhage, thrombosis) and emergencies must take place even as the diagnostic evaluation is proceeding. (See <a href=\"#H28\" class=\"local\">'Management'</a> below.)</p><p class=\"headingAnchor\" id=\"H503942772\"><span class=\"h2\">Diagnosis established by initial evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For many patients, the initial evaluation will define the cause of thrombocytosis.</p><p>No further testing or follow-up is required if one or two subsequent complete blood counts (CBCs) reveal that the platelet count responded as expected in the setting of reactive thrombocytosis. The interval between confirmatory CBCs will vary with clinical setting, as described below.</p><p>As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Iron deficiency</strong> &ndash; If iron repletion leads to normalization of the platelet count within one to two months. (See <a href=\"topic.htm?path=treatment-of-iron-deficiency-anemia-in-adults#H9250324\" class=\"medical medical_review\">&quot;Treatment of iron deficiency anemia in adults&quot;, section on 'Response to iron supplementation'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Infection </strong>&ndash; If thrombocytosis resolves with observation or treatment of an infection. The period for resolution of thrombocytosis will vary with the type and duration of infection. As examples, thrombocytosis should resolve within two weeks of a viral infection, but may persist for months or years with chronic infections.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Recovery from thrombocytopenia</strong> &ndash; Rebound thrombocytosis following resolution of thrombocytopenia caused by cytotoxic chemotherapy, vitamin deficiency, or immune thrombocytopenic purpura (ITP) should resolve within two to four weeks.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Inflammation</strong> &ndash; Thrombocytosis may persist in the setting of ongoing inflammation from a rheumatologic condition, cancer, or other chronic inflammatory condition. Further evaluation of thrombocytosis is not required if the platelet count does not rise significantly in the setting of ongoing inflammation.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Asplenia</strong> &ndash; Persistent thrombocytosis should be anticipated after surgical splenectomy or functional asplenia (eg, sickle cell disease), but other contributing factors should be considered if the platelet count rises significantly after establishing a stable level of thrombocytosis.</p><p/><p class=\"headingAnchor\" id=\"H1561132762\"><span class=\"h2\">Other scenarios</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For conditions that are not explained by the initial evaluation and for patients with reactive thrombocytosis that does not respond as expected, further testing is guided by clinical findings, as described below.</p><p class=\"headingAnchor\" id=\"H2736885280\"><span class=\"h3\">Suspected myeloproliferative neoplasm</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with vasomotor or constitutional symptoms, splenomegaly, <span class=\"nowrap\">and/or</span> an unusual thrombotic presentation should be evaluated for a myeloproliferative neoplasm (MPN), as discussed above. (See <a href=\"#H1531610461\" class=\"local\">'Our approach'</a> above.)</p><p>In this setting, we suggest the following tests of peripheral blood:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Mutation analysis of <em>JAK2, CALR, </em>and <em>MPL</em> to detect essential thrombocythemia (ET), polycythemia vera (PV), or primary myelofibrosis (PMF). Details of testing for Philadelphia chromosome-negative MPNs are provided separately. (See <a href=\"topic.htm?path=overview-of-the-myeloproliferative-neoplasms#H12\" class=\"medical medical_review\">&quot;Overview of the myeloproliferative neoplasms&quot;, section on 'Mutations in PV, ET, and PMF'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Molecular testing for <em>BCR-ABL1</em> <strong>or</strong> cytogenetic testing (eg, karyotype, fluorescence in situ hybridization [FISH]) for t(9;22) (Philadelphia chromosome) to diagnose chronic myeloid leukemia (CML), as discussed separately. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-chronic-myeloid-leukemia\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of chronic myeloid leukemia&quot;</a>.)</p><p/><p>An acceptable alternative is referral to a hematologist for this testing.</p><p>Patients who are diagnosed with an MPN, and those suspected of having an MPN but with unrevealing <span class=\"nowrap\">molecular/cytogenetic</span> analysis should be referred for hematology consultation.</p><p class=\"headingAnchor\" id=\"H2919826695\"><span class=\"h3\">Abnormal blood smear</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Detection of worrisome findings on the blood smear requires prompt evaluation. (See <a href=\"topic.htm?path=evaluation-of-the-peripheral-blood-smear#H34\" class=\"medical medical_review\">&quot;Evaluation of the peripheral blood smear&quot;, section on 'Worrisome findings'</a>.)</p><p>Examples include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Circulating leukemic blasts requires prompt referral to hematology for evaluation of possible acute leukemia. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-myeloid-leukemia\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Leukoerythroblastic findings (eg, nucleated red blood cells, teardrop cells) suggest a myelophthisic process (eg, PMF or other bone marrow infiltrative disorder), and requires prompt referral to hematology for further evaluation and management. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-primary-myelofibrosis#H3141935\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of primary myelofibrosis&quot;, section on 'Diagnosis'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H2528205724\"><span class=\"h3\">Familial thrombocytosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with an unexplained family history of thrombocytosis who are suspected of having familial <span class=\"nowrap\">thrombocytosis/essential</span> thrombocythemia, we suggest referral to a hematologist with expertise in such conditions. (See <a href=\"topic.htm?path=diagnosis-and-clinical-manifestations-of-essential-thrombocythemia#H26\" class=\"medical medical_review\">&quot;Diagnosis and clinical manifestations of essential thrombocythemia&quot;, section on 'Familial essential thrombocythemia'</a>.)</p><p class=\"headingAnchor\" id=\"H1449133490\"><span class=\"h2\">Referral to hematology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Referral to a hematologist is <strong>not</strong> required when the diagnosis is defined by the initial evaluation and the platelet count responds as expected to observation or treatment. (See <a href=\"#H503942772\" class=\"local\">'Diagnosis established by initial evaluation'</a> above.)</p><p>Patients with thrombocytosis who may benefit from referral to hematology include (see <a href=\"#H1561132762\" class=\"local\">'Other scenarios'</a> above):</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Platelet count did not respond as expected to observation <span class=\"nowrap\">and/or</span> treatment of a reactive cause of thrombocytosis</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diagnosis was not defined by initial evaluation</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>MPN or other primary hematologic disorder was detected by molecular testing, or is suspected (see <a href=\"#H1531610461\" class=\"local\">'Our approach'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Family history of unexplained thrombocytosis</p><p/><p>Most patients with thrombocytosis do not require bone marrow examination, but those who may require bone marrow examination include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>ET, PV, PMF, or CML defined by molecular <span class=\"nowrap\">and/or</span> cytogenetic testing (see <a href=\"#H2736885280\" class=\"local\">'Suspected myeloproliferative neoplasm'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Leukoerythroblastic features that suggest PMF or other bone marrow infiltrative disorder (see <a href=\"#H2919826695\" class=\"local\">'Abnormal blood smear'</a> above)</p><p/><p class=\"headingAnchor\" id=\"H28\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Management of thrombocytosis, related symptoms, and complications is informed by the underlying cause and the level and trajectory of the platelet count, as follows:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Reactive thrombocytosis:</strong></p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Asymptomatic patients</strong> &ndash; For patients whose diagnosis was established by the initial evaluation and whose platelet count responded as anticipated, no further evaluation or management is required, as described above. (See <a href=\"#H503942772\" class=\"local\">'Diagnosis established by initial evaluation'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong><span class=\"nowrap\">Persistent/worsening</span> thrombocytosis</strong> &ndash; For patients with <span class=\"nowrap\">persistent/worsening</span> thrombocytosis, or whose platelet count did not respond as anticipated in the setting of a reactive process (eg, infection, inflammatory conditions, cancer), other contributing factors should be considered; referral to hematology may be helpful.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Hemorrhage</strong> &ndash; Management of bleeding is guided by the location and severity of bleeding, as with other patients.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Thrombosis</strong> &ndash; Arterial or venous thrombosis is managed according to the nature of the thrombotic event, with anticoagulation, thrombolysis, <span class=\"nowrap\">and/or</span> other therapeutic interventions. Management is not altered based on the platelet count, per se.</p><p/><p class=\"bulletIndent2\">We suggest <strong>not</strong> treating reactive thrombocytosis with <a href=\"topic.htm?path=aspirin-drug-information\" class=\"drug drug_general\">aspirin</a>, cytoreductive therapy, or plateletpheresis, regardless of the level of the platelet count.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Autonomous thrombocytosis - </strong>Management is guided by the underlying disease process and any associated symptoms or complications.</p><p/><p class=\"bulletIndent1\">Management of the platelet count, vasogenic or constitutional symptoms, <span class=\"nowrap\">and/or</span> thrombosis is described separately. (See <a href=\"topic.htm?path=prognosis-and-treatment-of-polycythemia-vera#H2797858499\" class=\"medical medical_review\">&quot;Prognosis and treatment of polycythemia vera&quot;, section on 'Risk stratified management'</a> and <a href=\"topic.htm?path=prognosis-and-treatment-of-essential-thrombocythemia#H8\" class=\"medical medical_review\">&quot;Prognosis and treatment of essential thrombocythemia&quot;, section on 'Management'</a>.)</p><p/><p class=\"bulletIndent1\">Patients with extreme thrombocytosis <span class=\"nowrap\">(&gt;1,000,000/microL)</span> in the setting of an MPN may have excessive bleeding from acquired von Willebrand disease; diagnosis and management of this syndrome is discussed separately. (See <a href=\"topic.htm?path=prognosis-and-treatment-of-essential-thrombocythemia#H3810641968\" class=\"medical medical_review\">&quot;Prognosis and treatment of essential thrombocythemia&quot;, section on 'Extreme thrombocytosis'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H838964957\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-myeloproliferative-disorders\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Myeloproliferative disorders&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H32\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thrombocytosis is defined as a platelet count <span class=\"nowrap\">&gt;450,000/microL</span> (&gt;450 x 10<sup>9</sup><span class=\"nowrap\">/L)</span> in adults and children. (See <a href=\"#H2635508307\" class=\"local\">'Definitions and normal values'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Causes of thrombocytosis include:</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Reactive processes</strong> &ndash; Iron <span class=\"nowrap\">deficiency/blood</span> loss, infection, inflammation, post-splenectomy (<a href=\"image.htm?imageKey=HEME%2F74148\" class=\"graphic graphic_table graphicRef74148 \">table 1</a>) (see <a href=\"#H2536454853\" class=\"local\">'Reactive thrombocytosis'</a> above)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span><strong>Autonomous processes</strong> &ndash; Myeloproliferative neoplasms (MPN) and other hematologic malignancies, familial thrombocytosis (see <a href=\"#H404271305\" class=\"local\">'Autonomous thrombocytosis'</a> above)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Initial evaluation should seek to determine the cause of thrombocytosis and promptly assess medical emergencies; management of emergency conditions should not be delayed by evaluation of the cause of thrombocytosis. (See <a href=\"#H1020354520\" class=\"local\">'Initial evaluation'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>The urgency of evaluation is guided by the patient's clinical condition (eg, clinical emergencies), the presence of worrisome findings, and the degree of thrombocytosis, as described above. (See <a href=\"#H3427437341\" class=\"local\">'Urgency of evaluation'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Initial evaluation of thrombocytosis includes repeat complete blood count (CBC) and differential count, review of the blood smear, history and physical examination, serum ferritin, and certain other laboratory tests (in select patients). (See <a href=\"#H1531610461\" class=\"local\">'Our approach'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Initial evaluation should seek to identify patients who are more likely to have an MPN or other autonomous cause of thrombocytosis, such as those with unexplained splenomegaly, erythromelalgia, pruritus, constitutional symptoms, atypical thrombotic presentations, or unexplained family history of thrombosis. (See <a href=\"#H1531610461\" class=\"local\">'Our approach'</a> above.)</p><p/><p class=\"bulletIndent2\">Such patients should be evaluated for a potential MPN by molecular testing of peripheral blood for MPN-associated mutations (ie, <em>JAK2, CALR, MPL, </em>and <em>BCR-ABL1</em>); an acceptable alternative is referral to hematology for this testing. Additional detail is provided above. (See <a href=\"#H2736885280\" class=\"local\">'Suspected myeloproliferative neoplasm'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Further evaluation is guided by the presumed cause of thrombocytosis, the presence of symptoms or complications, and subsequent platelet counts.</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with reactive thrombocytosis (eg, iron deficiency, infection, inflammation, recovery from thrombocytopenia, asplenia) whose platelet count responds as expected to observation or intervention, no further testing or follow-up is required. (See <a href=\"#H503942772\" class=\"local\">'Diagnosis established by initial evaluation'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>Further evaluation is warranted for (see <a href=\"#H1561132762\" class=\"local\">'Other scenarios'</a> above):</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Reactive thrombocytosis with <span class=\"nowrap\">persistent/rising</span> platelet count that did not respond as anticipated; in this setting, other causes should be considered and referral to hematology may be useful.</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Patients suspected of having an MPN, but whose molecular testing was unrevealing, should be referred to hematology for evaluation.</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Worrisome findings on blood smear (eg, leukemic blasts, leukoerythroblastic pattern) should be referred promptly to hematology for further evaluation.</p><p/><p class=\"bulletIndent3\"><span class=\"glyph\">&#45;</span>Unexplained family history of thrombocytosis should be referred to a hematologist with expertise in such disorders. (See <a href=\"topic.htm?path=diagnosis-and-clinical-manifestations-of-essential-thrombocythemia#H26\" class=\"medical medical_review\">&quot;Diagnosis and clinical manifestations of essential thrombocythemia&quot;, section on 'Familial essential thrombocythemia'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Management of thrombocytosis, related symptoms, and complications is informed by the underlying cause, as described above. (See <a href=\"#H28\" class=\"local\">'Management'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/1\" class=\"nounderline abstract_t\">Teofili L, Larocca LM. Advances in understanding the pathogenesis of familial thrombocythaemia. Br J Haematol 2011; 152:701.</a></li><li><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/2\" class=\"nounderline abstract_t\">Buss DH, Cashell AW, O'Connor ML, et al. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med 1994; 96:247.</a></li><li><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/3\" class=\"nounderline abstract_t\">Hutchinson CV, Stelfox P, Rees-Unwin KS. Needle-like cryoglobulin crystals presenting as spurious thrombocytosis. Br J Haematol 2006; 135:280.</a></li><li><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/4\" class=\"nounderline abstract_t\">Ballard HS, Sidhu G. Cytoplasmic fragments causing spurious platelet counts in hairy cell leukemia: ultrastructural characterization. Arch Intern Med 1981; 141:942.</a></li><li><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/5\" class=\"nounderline abstract_t\">Berkessy S. [Cytoplasm fragmentation of malignant lymphoma cells]. Folia Haematol Int Mag Klin Morphol Blutforsch 1983; 110:651.</a></li><li><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/6\" class=\"nounderline abstract_t\">Lawrence C, Atac B. Hematologic changes in massive burn injury. Crit Care Med 1992; 20:1284.</a></li><li><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/7\" class=\"nounderline abstract_t\">Uppenkamp M, Makarova E, Petrasch S, Brittinger G. Thrombopoietin serum concentration in patients with reactive and myeloproliferative thrombocytosis. Ann Hematol 1998; 77:217.</a></li><li><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/8\" class=\"nounderline abstract_t\">Wang JC, Chen C, Novetsky AD, et al. Blood thrombopoietin levels in clonal thrombocytosis and reactive thrombocytosis. Am J Med 1998; 104:451.</a></li><li><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/9\" class=\"nounderline abstract_t\">Hou M, Carneskog J, Mellqvist UH, et al. Impact of endogenous thrombopoietin levels on the differential diagnosis of essential thrombocythaemia and reactive thrombocytosis. Eur J Haematol 1998; 61:119.</a></li><li><a href=\"https://www.uptodate.com/contents/approach-to-the-patient-with-thrombocytosis/abstract/10\" class=\"nounderline abstract_t\">Cerutti A, Custodi P, Duranti M, et al. Thrombopoietin levels in patients with primary and reactive thrombocytosis. Br J Haematol 1997; 99:281.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 6682 Version 23.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H32\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2635508307\" id=\"outline-link-H2635508307\">DEFINITIONS AND NORMAL VALUES</a></li><li><a href=\"#H352081854\" id=\"outline-link-H352081854\">CAUSES OF THROMBOCYTOSIS</a><ul><li><a href=\"#H2536454853\" id=\"outline-link-H2536454853\">Reactive thrombocytosis</a></li><li><a href=\"#H404271305\" id=\"outline-link-H404271305\">Autonomous thrombocytosis</a><ul><li><a href=\"#H1947117540\" id=\"outline-link-H1947117540\">- Hematologic malignancies</a></li><li><a href=\"#H2724242692\" id=\"outline-link-H2724242692\">- Familial thrombocytosis</a></li></ul></li></ul></li><li><a href=\"#H1020354520\" id=\"outline-link-H1020354520\">INITIAL EVALUATION</a><ul><li><a href=\"#H3427437341\" id=\"outline-link-H3427437341\">Urgency of evaluation</a></li><li><a href=\"#H1531610461\" id=\"outline-link-H1531610461\">Our approach</a></li><li><a href=\"#H2977161337\" id=\"outline-link-H2977161337\">Complete blood count (CBC)</a></li><li><a href=\"#H3885038087\" id=\"outline-link-H3885038087\">Blood smear</a></li><li><a href=\"#H2380812066\" id=\"outline-link-H2380812066\">History and examination</a></li><li><a href=\"#H1864706616\" id=\"outline-link-H1864706616\">Other laboratory studies</a></li></ul></li><li><a href=\"#H73021206\" id=\"outline-link-H73021206\">FURTHER EVALUATION</a><ul><li><a href=\"#H503942772\" id=\"outline-link-H503942772\">Diagnosis established by initial evaluation</a></li><li><a href=\"#H1561132762\" id=\"outline-link-H1561132762\">Other scenarios</a><ul><li><a href=\"#H2736885280\" id=\"outline-link-H2736885280\">- Suspected myeloproliferative neoplasm</a></li><li><a href=\"#H2919826695\" id=\"outline-link-H2919826695\">- Abnormal blood smear</a></li><li><a href=\"#H2528205724\" id=\"outline-link-H2528205724\">- Familial thrombocytosis</a></li></ul></li><li><a href=\"#H1449133490\" id=\"outline-link-H1449133490\">Referral to hematology</a></li></ul></li><li><a href=\"#H28\" id=\"outline-link-H28\">MANAGEMENT</a></li><li><a href=\"#H838964957\" id=\"outline-link-H838964957\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H32\" id=\"outline-link-H32\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"HEME/6682|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/61742\" class=\"graphic graphic_picture\">- Essential thrombocythemia</a></li><li><a href=\"image.htm?imageKey=HEME/60588\" class=\"graphic graphic_picture\">- Howell-Jolly bodies</a></li><li><a href=\"image.htm?imageKey=HEME/50601\" class=\"graphic graphic_picture\">- Nucleated RBC in AIHA</a></li><li><a href=\"image.htm?imageKey=HEME/68110\" class=\"graphic graphic_picture\">- Leukoerythroblastic blood smear</a></li><li><a href=\"image.htm?imageKey=HEME/56954\" class=\"graphic graphic_picture\">- CML blood smear</a></li><li><a href=\"image.htm?imageKey=HEME/71990\" class=\"graphic graphic_picture\">- Pelger-Huet anomaly</a></li><li><a href=\"image.htm?imageKey=HEME/64267\" class=\"graphic graphic_picture\">- Blood smear, iron deficiency</a></li><li><a href=\"image.htm?imageKey=HEME/70248\" class=\"graphic graphic_picture\">- Toxic granulations</a></li></ul></li><li><div id=\"HEME/6682|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=HEME/74148\" class=\"graphic graphic_table\">- Causes of reactive thrombocytosis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=causes-and-diagnosis-of-iron-deficiency-and-iron-deficiency-anemia-in-adults\" class=\"medical medical_review\">Causes and diagnosis of iron deficiency and iron deficiency anemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=causes-and-evaluation-of-hyperkalemia-in-adults\" class=\"medical medical_review\">Causes and evaluation of hyperkalemia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-chronic-myeloid-leukemia\" class=\"medical medical_review\">Clinical manifestations and diagnosis of chronic myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-polycythemia-vera\" class=\"medical medical_review\">Clinical manifestations and diagnosis of polycythemia vera</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-primary-myelofibrosis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of primary myelofibrosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-the-myelodysplastic-syndromes\" class=\"medical medical_review\">Clinical manifestations and diagnosis of the myelodysplastic syndromes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-acute-myeloid-leukemia\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnosis-and-clinical-manifestations-of-essential-thrombocythemia\" class=\"medical medical_review\">Diagnosis and clinical manifestations of essential thrombocythemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=diagnostic-approach-to-the-patient-with-polycythemia\" class=\"medical medical_review\">Diagnostic approach to the patient with polycythemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-of-the-peripheral-blood-smear\" class=\"medical medical_review\">Evaluation of the peripheral blood smear</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=megakaryocyte-biology-and-the-production-of-platelets\" class=\"medical medical_review\">Megakaryocyte biology and the production of platelets</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-the-myeloproliferative-neoplasms\" class=\"medical medical_review\">Overview of the myeloproliferative neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=platelet-biology\" class=\"medical medical_review\">Platelet biology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=platelet-function-testing\" class=\"medical medical_review\">Platelet function testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prognosis-and-treatment-of-essential-thrombocythemia\" class=\"medical medical_review\">Prognosis and treatment of essential thrombocythemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=prognosis-and-treatment-of-polycythemia-vera\" class=\"medical medical_review\">Prognosis and treatment of polycythemia vera</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-myeloproliferative-disorders\" class=\"medical medical_society_guidelines\">Society guideline links: Myeloproliferative disorders</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-iron-deficiency-anemia-in-adults\" class=\"medical medical_review\">Treatment of iron deficiency anemia in adults</a></li></ul></div></div>","javascript":null}